Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
rhuFab V2 · 6 trials · 4 indications
| Name | Type | Description |
|---|---|---|
| rhuFab V2 (ranibizumab) | DRUG | - |
Inclusion Criteria: * Signed Informed Consent Form * Age ≥ 50 years * Subfoveal CNV secondary to AMD, with evidence of recent disease progression, as defined by any of the following (lesion is eligible if it meets any one of the following criteria): ≥ 5 letters (or ≥ 1 Snellen line) of BCVA lost wi...
rhuFab V2 is an investigational drug being studied for the treatment of choroidal neovascularization, macular degeneration, and age-related maculopathy. It is administered via intravitreal injection and is being developed for ophthalmology indications.
rhuFab V2 is being developed by Roche Holding AG, which trades under the ticker RHHBY. The company is conducting clinical trials to evaluate the drug for the treatment of eye conditions such as age-related macular degeneration.
rhuFab V2 is in Phase 1 clinical development. It has completed four clinical trials, including Phase 1 and Phase 3 studies, but it remains investigational and has not been approved by regulatory authorities.
rhuFab V2 has completed four clinical trials, including NCT00056823, a Phase 1 study combining the drug with Visudyne in age-related maculopathy; NCT00056836 and NCT00061594, both Phase 3 studies in macular degeneration; and NCT00251459, a Phase 3 study in choroidal neovascularization secondary to age-related macular degeneration.
rhuFab V2 is also known as ranibizumab. One of its completed trials, NCT00251459, is titled 'A Study to Evaluate Ranibizumab in Subjects With Choroidal Neovascularization (CNV) Secondary to Age-Related Macular Degeneration (AMD),' confirming the alternative name.